Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data

Annals of the Rheumatic Diseases

Volumn 65, Issue 3, 2006, Pages 285-293

  Da Silva, J A P ^a   Jacobs, J W G ^b   Kirwan, J R ^c   Boers, M ^d   Saag, K G ^e   Ines L B S ^a   De Koning, E J P ^f   Buttgereit, F ^g   Cutolo, M ^h   Capell, H ⁱ   Rau, R ^j   Bijlsma, J W J ^b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e The University of Alabama at Birmingham   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ GLASGOW ROYAL INFIRMARY   (United Kingdom)

^j Evangelisches Fachkrankenhaus ^*  (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CONTRACEPTIVE AGENT; DEFLAZACORT; DEXAMETHASONE; ERYTHROMYCIN; GLUCOCORTICOID; INDOMETACIN; KETOCONAZOLE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISOLONE; PREDNISONE; RIFAMPICIN; SALICYLIC ACID; TROLEANDOMYCIN; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ACNE; ATHEROSCLEROSIS; BACTERIAL INFECTION; BEHAVIOR DISORDER; BLINDNESS; BONE NECROSIS; CAPILLARY RESISTANCE; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; ELECTROMYOGRAPHY; ENDOCRINE DISEASE; EYE DISEASE; GASTROINTESTINAL DISEASE; GLAUCOMA; GLUCOSE INTOLERANCE; HAIR DISEASE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTENSION; HYPOKALEMIA; INFLAMMATORY DISEASE; LOW DRUG DOSE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MOOD DISORDER; MUSCULOSKELETAL DISEASE; MYCOSIS; MYOPATHY; OBESITY; OSTEOPOROSIS; PANCREATITIS; PARASITOSIS; PEPTIC ULCER; PRIORITY JOURNAL; PSYCHOSIS; PURPURA; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SKIN ATROPHY; SKIN DISEASE; SODIUM RETENTION; STRIA; SUDDEN DEATH; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; VISUAL IMPAIRMENT; WATER RETENTION; WOUND HEALING IMPAIRMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; MUSCULOSKELETAL DISEASES; RANDOMIZED CONTROLLED TRIALS;

EID: 33144484825     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.038638     Document Type: Review

References (164)

1. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.
2. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 1998;37:930-6.
3. Wassenberg S, Rau R, Steinfefd P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80.
4. van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
5. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004;63:797-803.
6. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-8.
7. de Nijs RN, Jacobs JW, Bijlsma JW, Lems WF, Laan RF, Houben HH, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:1375-83.
8. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
9. Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981;24:892-8.
10. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983;25:615-20.
11. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997;24:1495-503.
12. Lodder MC, Lems WF, Kostense PJ, Verhoeven AC, Dijkmans BA, Boers M. Bone loss due to glucocorticoids: update of a systematic review op prospective studies in rheumatoid arthritis and other diseases [abstract]. Ann Rheum Dis 2003;62(suppl 1):94.
13. Bijlsma JWJ. Long-term glucocorticoid treatment of rheumatoid arthritis: risk or benefit? Rheumatology in Europe 1998;27:67-71.
14. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis or serious adverse events. Am J Med 1994;96:115-23.
15. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
16. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990;150:2545-8.
17. Lems WF, Jahangier ZN, Jacobs JW, Bijlsma JW. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995;13:293-7.
18. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 2000;160:2917-22.
19. Sambrook P, Lane NE. Corticosteroid osteoporosis. Best Pract Res Clin Rneumatol 2001;15:401-13.
20. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
21. Dequeker J, Westhovens R, Luyten FP. Rheumatic disorders and glucocorticoid-induced osteoporosis. Front Harm Res 2002;30:107-20.
22. Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2002;41:1088-94.
23. Anonymous. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-lnduced Osteoporosis. Arthritis Rheum 2001;44:1496-503.
24. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-92.
25. Anonymous. Guidelines on the prevention and treatment of glucocorticoid induced osteoporosis by the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians, http://www.rcplondon.ac.uk/pubs/books/ glucocorticoid (accessed 21 November 2004).
26. Ninomija S. An epidemiologic survey of idiopathic avascular necrosis of the femoral head in Japan. Annual Report of Japanese Investigation Committee for Intractable Disease. Osaka: University Publisher, 1984.
27. Zizic TM, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985;79:596-604.
28. Gebhard KL, Maibach HI. Relationship between systemic corticosteroids and osteonecrosis. Am J Clin Dermatol 2001;2:377-88.
29. Vreden SG, Hermus AR, van Liessum PA, Pieters GF, Smals AG, Kloppenborg PW. Aseptic bone necrosis in patients on glucocorticoid replacement therapy. Neth J Med 1991;39:153-7.
30. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
31. Klipple JH. Osteonecrosis. Primer on the rheumatic diseases. Atlanta, USA: Arthritis Foundation, 2001:503-6.
32. Kagen LJ. Steroid myopathy. In: Lin NA, Paget SA, eds. Principles of corticosteroid therapy. London: Arnold, 2002:87-90.
33. Danneskiold-Samsoe B, Grimby G. The influence of prednisone on the muscle morphology and muscle enzymes in patients with rheumatoid arthritis. Clin Sci (Lond) 1986;71:693-701.
34. Moxley RT. Metabolic and endocrine myopathies. In: Walton JN, Karpati G, Jones DH, eds. Disorders of voluntary muscle. Edinburgh: Churchil Livingstone, 1994:647.
35. Tayek JA, Katz J. Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: relationship to serum cortisol. Am J Physiol 1997;272:E476-84.
36. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997;100:2094-8.
37. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997;99:414-23.
38. Hosker JP, Burnett MA, Matthews DR, Turner RC. Prednisolone enhances beta-cell function independently of ambient glycemic levels in type II diabetes. Metabolism 1993;42:1116-20.
39. Kautzky-Willer A, Thomaseth K, Clodi M, Ludvik B, Waldhausl W, Prager R, et al. Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metabolism 1996;45:486-91.
40. Tounian P, Schneiter P, Henry S, Delarue J, Tappy L. Effects of dexamethasone on hepatic glucose production and fructose metabolism in healthy humans. Am J Physiol 1997;273:E315-20.
41. Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997;26:631-45.
42. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999;25:489-505.
43. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
44. Black DM, Filak AT. Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection. J Fam Pract 1989;28:462-3.
45. Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991;51:374-7.
46. Liapi C, Chrousos GP. Glucocorticoids. In: Yaffe SJ, Arand JV, eds. Pediatric pharmacology. Philadelphia: Sounders, 1992:466.
47. Bruno A, Cavallo-Perin P, Cassader M, Pagano G. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. Arch Intern Med 1987;147:679-80.
48. Greenstone MA, Shaw AB. Alternate day corticosteroid causes alternate day hyperglycaemia. Postgrad Med J 1987;63:761-4.
49. Barbosa J, Menth L, Eaton J, Sutherland D, Freier EF, Najarian J. Long-term, ambulatory, subcutaneous insulin infusion versus multiple daily injections in brittle diabetic patients. Diabetes Care 1981;4:269-74.
50. Ekstrand A, Ahonen J, Gronhagen-Riska C, Groop L. Mechanisms of insulin resistance after kidney transplantation. Transplantation 1989;48:563-8.
51. Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997;3:575-9.
52. Stewart PM, Tomlinson JW. Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol Metab 2002;13:94-6.
53. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, et al. Regulation of expression of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 2001;142:1982-9.
54. Reilly JJ, Brougham M, Montgomery C, Richardson F, Kelly A, Gibson BE. Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 2001;86:3742-5.
55. Tataranni PA, Larson DE, Snitker S, Younq JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996;271:E317-25.
56. Nordin BE, Crilly RG, Marshall DH, Barkworth SA. Oestrogens, the menopause and the adrenopause. J Endocrinol 1981;89(suppl):13-43P.
57. Hampson G, Bhargava N, Cheung J, Vaja S, Seed PT, Fogelman I. Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. Metabolism 2002;51:1458-62.
58. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-51.
59. Cumming DC, Quigley ME, Yen SS. Acute suppression of circulating testosterone levels by cortisol in men. J Clin Endocrinol Metab 1983;57:671-3.
60. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000;160:610-19.
61. Becker DM, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman KL, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988;85:632-8.
62. Cattran DC, Steiner G, Wilson DR, Fenton SA. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med 1979;91:554-9.
63. Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 1982;22:42-7.
64. el-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. BMJ 1973;2:85-6.
65. MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992;51:152-5.
66. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992;71:291-302.
67. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994;21:1264-7.
68. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr. Jansen-McWilliams L, et al. Age-specific incidence rates or myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study, Am J Epidemiol 1997;145:408-15.
69. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-19.
70. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
71. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
72. Asai K, Funaki C, Hayashi T, Yamada K, Naito M, Kuzuya M, et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb 1993;13:892-9.
73. Munford RS. Statins and the acute-phase response. N Engl J Med 2001;344:2016-18.
74. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
75. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
76. Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987;5:425-33.
77. Bia JM, Tyler K, DeFronzo RA. The effect of dexamethasone on renal electrolyte excretion in the adrenalectomized rat. Endocrinology 1982;111:882-8.
78. Campen TJ, Vaughn DA, Fanestil DD. Mineralo- and glucocorticoid effects on renal excretion of electrolytes. Pflugers Arch 1983;399:93-101.
79. Hall JE, Morse CL, Smith MJ Jr, Young DB, Guyton AC. Control of arterial pressure and renal function during glucocorticoid excess in dogs. Hypertension 1980;2:139-48.
80. Kohlmann O, Ribeiro AB, Marson O, Saragoca MA, Ramos OL. Methylprednisolone-induced hypertension. Role for the autonomic and renin angiotensin systems. Hypertension 1981;3:11-11.
81. Krakoff LR, Selvadurai R, Sutter E. Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat. Am J Physiol 1975;228:613-17.
82. Kurokawa K, Fukagawa M, Hayashi M, Saruta T. Renal receptors and cellular mechanisms of hormone action in the kidney. In: Seldin DW, Giebisch G, eds. The kidney: physiology and pathophysiology. New York: Raven Press, 1992:1339-72.
83. Nakamoto H, Suzuki H, Kageyama Y, Ohishi A, Murakami M, Naitoh M, et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A 1991;13:587-606.
84. Nelson MA, Coqhlan JP, Denton DA, Mills EH, Spence CD, Scoggins BA. Metabolic and blood pressure effects of 6 alpha-methylprednisolone in the conscious sheep. Clin Exp Hypertens A 1984;6:1067-75.
85. Okuno T, Suzuki H, Saruta T. Dexamethasone hypertension in rats. Clin Exp Hypertens 1981;3:1075-86.
86. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989;7:537-49.
87. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 1989;117:876-82.
88. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-75.
89. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987;31:1213-24.
90. Shelter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16:505-11.
91. Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond) 1981;61(suppl 7):381-3s.
92. McHugh MI, Tanboga H, Wilkinson R. Alternate day steroids and blood pressure control after renal transplantation. Proc Eur Dial Transplant Assoc 1980;17:496-501.
93. Singh RG, Kassir M, Roistacher N, Lerman BB, Kligfield P. Acceleration of atrioventricular conduction during corticosteroid therapy. Am Heart J 1993;125:1432-4.
94. Smith RS, Warren DJ. Effects of high-dose intravenous methylprednisolone on circulation in humans. Transplantation 1983;35:349-51.
95. Thompson JF, Chalmers DH, Wood RF, Kirkham SR, Morris PJ. Sudden death following high-dose intravenous methylprednisolone. Transplantation 1983;36:594-6.
96. Wolverton SE. Corticosteroids and the integument. In: Lin AN, Paget SA, eds. Principles of corticosteroid therapy. London: Arnold, 2002:166-72.
97. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000;106:651-9.
98. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86:3562-7.
99. Tornatore KM, Biocevich DM, Reed K, Tousley K, Singh JP, Venuto RC. Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation 1995;59:729-36.
100. Pedrosa MC, Rohrer RM, Kaplan MM. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. Clin Transplant 1995;9:322-5.
101. Davis GF. Adverse effects of corticosteroids: II. Systemic. Clin Dermatol 1986;4:161-9.
102. Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991;21:1-11.
103. Hatz HJ, Helmke K. [Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy]. Z Rheumatol 1992;51:213-21.
104. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Chappell RJ. Changes in visual acuity in a population over a 10-year period: The Beaver Dam Eye Study. Ophthalmology 2001;108:1757-66.
105. Rooklin AR, Lampert SI, Jaeger EA, McGeady SJ, Mansmann HC Jr. Posterior subcapsular cataracts in steroid-requiring asthmatic children. J Allergy Clin Immunol 1979;63:383-6.
106. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging 1999;15:439-50.
107. Klemetti A. The dexamethasone provocative test: a predictive tool for glaucoma? Acta Ophthalmol (Copenh) 1990;68:29-33.
108. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, et al. Identification of a gene that causes primary open angle glaucoma. Science 1997;275:668-70.
109. Akingbehin AO. Corticosteroid-induced ocular hypertension. I. Prevalence in closed-angle glaucoma. Br J Ophthalmol 1982;66:536-40.
110. Brodie S. Corticosteroids and the eye. In: Lin AN, Paget SA, eds. Principles of corticosteroid therapy. London: Arnold, 2002:131-4.
111. Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976;294:473-9.
112. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32.
113. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309:21-4.
114. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
115. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001;3:98-101.
116. Carone FA, Liebow AA. Acute pancreatic lesions in patients treated with AQH and adrenal corticoids. N Engl J Med 1957;257:690-7.
117. Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. J Rheumatol 1998;25:801-6.
118. Singh AE, Tyrrell DL. Corticosteroids in infectious diseases. In: Lin AN, Paget SA, eds. Principles of corticosteroid therapy, London: Arnold, 2002:285-306.
119. Baxter JD. Minimizing the side effects of glucocorticoid therapy. Adv Intern Med 1990;35:173-93.
120. Dale DC, Fauci AS, Wolff SM. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med 1974;291:1154-8.
121. Dale DC, Petersdorf RG. Corticosteroids and infectious diseases. Med Clin North Am 1973;57:1277-87.
122. Stracher AR, Soave R. Infectious complications of corticosteroid therapy. In: Linn AN, Paget SA, eds. Principles of corticosteroid therapy. London: Arnold, 2002:419-30.
123. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
124. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21:246-51.
125. Hellmann DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 1987;66:341-8.
126. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13.
127. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 1983;5:319-32.
128. Gourley MF, Austin HA, III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann intern Med 1996;125:549-57.
129. Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax 1968;23:571-81.
130. Demopoulos A, Apatoff BR. Corticosteroids and the nervous system. In: Lin NA, Paget SA, eds. Principles of corticosteroid therapy. London: Arnold, 2002:150-65.
131. Patten SB, Neutel Cl. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf 2000;22:111-22.
132. Naber D, Sand P, Heigl B. Psycnopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996;21:25-31.
133. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992;128:1467-73.
134. Reckart MD, Eisendrath SJ. Exogenous corticosteroid effects on mood and cognition: case presentations. Int J Psychosom 1990;37:57-61.
135. Tanner AR, Caffin JA, Halliday JW, Powell LW. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol 1979;7:397-400.
136. Uribe M, Casian C, Rojas S, Sierra JG, Go VL. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology 1981;80:661-5.
137. Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972;286:1125-8.
138. Evans PJ, Walker RF, Peters JR, Dyas J, Riad-Fahmy D, Thomas JP, et al. Anticonvulsant therapy and Cortisol elimination. Br J Clin Pharmacol 1985;20:129-32.
139. Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 1984;14:1-6.
140. Frey FJ, Frey BM. Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J Lab Clin Med 1983;101:593-604.
141. Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1977;22:912-16.
142. Stjernholm MR, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. J Clin Endocrinol Metab 1975;41:887-93.
143. Edwards OM, Courtenay-Evans RJ, Galley JM, Hunter J, Tait AD. Changes in cortisol metabolism following rifampicin therapy. Lancet 1974;2:548-51.
144. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med 1994;154:1521-4.
145. Kawai S, Ichikawa Y, Homma M. [Rifampicin-induced resistance to prednisolone treatment in collagen disease-a pharmacokinetic study]. Ryumachi 1984;24:32-7.
146. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. BMJ (Clin Res Ed) 1983;286:923-5.
147. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984;59:1204-6.
148. Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 1983;56:702-9.
149. Frey BM, Schaad HJ, Frey FJ. Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur J Clin Pharmacol 1984;26:505-11.
150. Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986;62:234-7.
151. Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 1986;40:301-8.
152. LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983;72:34-9.
153. Szefler SJ, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clin Pharmacol Ther 1982;32:166-71.
154. Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak AM, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin- steroid therapy. J Allergy Clin Immunol 1982;69:455-60.
155. Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther 1991;49:558-70.
156. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989;45:366-72.
157. Roe SA, Williams IA, English J, Baylis EM. Alteration of plasma prednisolone levels by indomethacin and naproxen. Br J Clin Pharmacol 1982;14:459-61.
158. Kaufman M. Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. Mult Scler 1997;3:248-9.
159. Klinenberg JR, Miller F. Effect of corticosteroids on blood salicylate concentration. JAMA 1965;194:601-4.
160. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000;27:1668-73.
161. Buttgereit F, Da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
162. Jacobs JW, Bijlsma JW. Interpretation of trial methodology not always easy: comment on the editorial by Landewé. Arthritis Rheum 2003;48:2693-4.
163. Huizenga NA, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H, et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998;83:144-51.
164. Rhen T, Cidlowski JA, et al. Antiinflammatory action of glucocorticoids - new mechanism for old drugs. N Engl J Med 2005;353:1711-23.